No abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mainly causes acute respiratory disease, but it can also cause multiple organ failure. 14% to 76.3% of Coronavirus disease 2019 (COVID-19) patients have abnormal liver function tests, 1-7 and these patients have been reported to be more likely to progress to severe pneumonia. However, these data come from Chinese populations, and there are no specific data on COVID-19 patients in Europe. This knowledge gap prompted us to study the prevalence of abnormal liver function tests and the relationship between abnormal liver function and clinical outcome in a multicentre cohort study of patients hospitalized with COVID-19 in France. 2 | ME THODS We retrospectively studied a cohort of COVID-19 patients hospitalized in two COVID-19 referral hospitals in France (CHU Montpellier

Background and Aims After 2 doses, the efficacy of anti‐SARS‐CoV‐2 vaccination seems to be lower in solid organ transplant recipients than in the immunocompetent population. The objective of this study was to determine the humoral response rate after vaccination, including with a booster dose, and to identify risk factors for non‐responsiveness in liver transplant recipients. Methods We included all patients seen in consultation in two French liver transplant centres between January 1, 2021, and March 15, 2021. Results 598 liver transplant recipients were enrolled and 327 were included for analysis. Sixteen patients received one dose, 63 patients two doses and 248 patients three doses. Anti‐SARS‐Cov‐2 antibodies were detected in 242 out of 327 (74.0%) liver transplant patients after vaccination. Considering an optimal serologic response defined as an antibody titre >260 BAU/ml, 172 patients (52.6%) were responders. Mycophenolate mofetil (MMF) treatment was an independent risk factor for a failure to develop anti‐SARS‐CoV‐2 antibodies after vaccination (OR 0.458; 95%CI 0.258–0.813; p = .008). Conversely, male gender (OR 2.247, 95%CI 1.194–4.227; p = .012) and receiving an mRNA vaccine (vs a non‐mRNA vaccine) (OR 4.107, 95%CI 1.145–14.731; p = .030) were independent predictive factors for developing an optimal humoral response after vaccination. None of the patients who received the vaccine experienced any serious adverse events. Conclusions Even after a third booster dose, response rate to vaccination is decreased in liver transplant recipients. MMF appears to be a major determinant of seroconversion and optimal response to vaccination in these patients.